BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
suven pharmaceuticals ltd stock

SUVEN PHARMACEUTICALS LTD Share Price

1265 -11.34 (-0.88%)
Dec 13 2024 03:29 PM Pharmaceuticals NSE: SUVENPHAR

SUVEN PHARMACEUTICALS LTD Share Price Update

As of the latest trading session, SUVEN PHARMACEUTICALS LTD share price is currently at 1265, which is down by -11.34 from its previous closing. Today, the stock has fluctuated between 1245.00 and 1282.75. Over the past year, SUVEN PHARMACEUTICALS LTD has achieved a return of 84.56 %. In the last month alone, the return has been 0.60 %. Read More...

SUVEN PHARMACEUTICALS LTD Performance

Day Range

Low1245.00 High1282.75
1270.00

52 Week Range

Low 585.20 High 1360.00
1270.00

SUVEN PHARMACEUTICALS LTD Share Price

17945

543064

SUVENPHAR

img img img img
No Data Available

Open Price

1275.95

Prev. Close

1276.35

Volume (Shares)

99935.00

Total traded value

1269.17

Upper Circuit

1531.60

Lower Circuit

1021.10

Note: The current prices & values are delayed, Login to your account for live updates.

SUVEN PHARMACEUTICALS LTD Fundamentals


(Standalone)

Market Cap (Cr) 32202.47
PE Ratio (TTM) 131.06
Book Value / Share 86.66
Beta 0.39
ROE 14.31%
EPS (TTM) 9.71
Dividend Yield 0.00%
Net Profit Qtr (Cr) 76.33

SUVEN PHARMACEUTICALS LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 236.06
Operating Expense 148.81
Net Profit 76.33
Net Profit Margin (%) 32.33
Earnings Per Share (EPS) 3.00
EBITDA 114.44
Effective Tax Rate (%) 24.18
Particulars JUN 2024 (Values in Cr)
Revenue 222.09
Operating Expense 152.65
Net Profit 65.07
Net Profit Margin (%) 29.29
Earnings Per Share (EPS) 2.56
EBITDA 100.99
Effective Tax Rate (%) 25.54
Particulars MAR 2024 (Values in Cr)
Revenue 243.52
Operating Expense 189.32
Net Profit 53.43
Net Profit Margin (%) 21.94
Earnings Per Share (EPS) 2.10
EBITDA 89.01
Effective Tax Rate (%) 24.79
Particulars DEC 2023 (Values in Cr)
Revenue 212.83
Operating Expense 157.29
Net Profit 52.36
Net Profit Margin (%) 24.60
Earnings Per Share (EPS) 2.06
EBITDA 83.02
Effective Tax Rate (%) 24.66
Particulars SEP 2023 (Values in Cr)
Revenue 224.62
Operating Expense 138.25
Net Profit 74.73
Net Profit Margin (%) 33.26
Earnings Per Share (EPS) 2.94
EBITDA 111.55
Effective Tax Rate (%) 25.69
Particulars MAR 2024 (Values in Cr)
Revenue 1024.99
Operating Expense 671.31
Net Profit 304.82
Net Profit Margin (%) 29.73
Earnings Per Share (EPS) 11.97
EBITDA 464.99
Effective Tax Rate (%) 25.42
Particulars MAR 2023 (Values in Cr)
Revenue 1330.08
Operating Expense 795.24
Net Profit 432.60
Net Profit Margin (%) 32.52
Earnings Per Share (EPS) 16.99
EBITDA 635.24
Effective Tax Rate (%) 25.33
Particulars MAR 2022 (Values in Cr)
Revenue 1320.22
Operating Expense 785.56
Net Profit 558.10
Net Profit Margin (%) 42.27
Earnings Per Share (EPS) 21.92
EBITDA 767.78
Effective Tax Rate (%) 22.74
Particulars MAR 2021 (Values in Cr)
Revenue 1009.72
Operating Expense 609.97
Net Profit 308.65
Net Profit Margin (%) 30.56
Earnings Per Share (EPS) 12.12
EBITDA 454.76
Effective Tax Rate (%) 25.44
Particulars MAR 2020 (Values in Cr)
Revenue 833.79
Operating Expense 494.31
Net Profit 270.08
Net Profit Margin (%) 32.39
Earnings Per Share (EPS) 21.21
EBITDA 399.76
Effective Tax Rate (%) 24.47
Particulars MAR 2024 (Values in Cr)
Book Value / Share 80.56
ROE % 14.11
ROCE % 18.69
Total Debt to Total Equity 0.04
EBITDA Margin 40.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.16
ROE % 25.21
ROCE % 33.22
Total Debt to Total Equity 0.05
EBITDA Margin 46.30
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.99
ROE % 29.79
ROCE % 40.62
Total Debt to Total Equity 0.09
EBITDA Margin 48.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 46.38
ROE % 35.78
ROCE % 40.45
Total Debt to Total Equity 0.16
EBITDA Margin 50.61
Particulars MAR 2020 (Values in Cr)
Book Value / Share 66.37
ROE % 44.58
ROCE % 49.77
Total Debt to Total Equity 0.19
EBITDA Margin 54.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 80.76
ROE % 14.31
ROCE % 18.82
Total Debt to Total Equity 0.04
EBITDA Margin 41.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.72
ROE % 26.46
ROCE % 34.28
Total Debt to Total Equity 0.05
EBITDA Margin 47.76
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.74
ROE % 43.17
ROCE % 51.45
Total Debt to Total Equity 0.09
EBITDA Margin 58.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.84
ROE % 33.40
ROCE % 38.83
Total Debt to Total Equity 0.18
EBITDA Margin 45.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 61.50
ROE % 39.71
ROCE % 45.81
Total Debt to Total Equity 0.20
EBITDA Margin 48.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 50.49
Total Assets 2254.08
Total Liabilities 2254.08
Total Equity 2050.66
Share Outstanding 254564960
Price to Book Ratio 8.38
Return on Assets (%) 13.32
Return on Capital (%) 14.37
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 68.01
Total Assets 1965.74
Total Liabilities 1965.74
Total Equity 1735.18
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 20.92
Return on Capital (%) 22.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.30
Total Assets 1829.58
Total Liabilities 1829.58
Total Equity 1527.18
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 24.80
Return on Capital (%) 27.97
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.65
Total Assets 1474.47
Total Liabilities 1474.47
Total Equity 1180.79
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 24.57
Return on Capital (%) 27.41
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 14.07
Total Assets 1172.81
Total Liabilities 1172.81
Total Equity 844.76
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 27.02
Return on Capital (%) 30.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 21.58
Total Assets 2240.71
Total Liabilities 2240.71
Total Equity 2055.89
Share Outstanding 254564960
Price to Book Ratio 8.38
Return on Assets (%) 13.60
Return on Capital (%) 14.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 46.23
Total Assets 1958.33
Total Liabilities 1958.33
Total Equity 1749.38
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 22.09
Return on Capital (%) 23.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 32.95
Total Assets 1804.88
Total Liabilities 1804.88
Total Equity 1520.69
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 30.92
Return on Capital (%) 34.53
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.56
Total Assets 1358.82
Total Liabilities 1358.82
Total Equity 1065.18
Share Outstanding 254564956
Price to Book Ratio 11.84
Return on Assets (%) 22.71
Return on Capital (%) 25.58
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 13.95
Total Assets 1110.88
Total Liabilities 1110.88
Total Equity 782.82
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 24.31
Return on Capital (%) 27.9
Particulars MAR 2024 (Values in Cr)
Net Income 405.67
Cash from Operations 468.43
Cash from Investing -362.25
Cash from Financing -13.80
Net change in Cash -17.57
Free Cash Flow 520.22
Particulars MAR 2023 (Values in Cr)
Net Income 559.72
Cash from Operations 602.95
Cash from Investing -195.00
Cash from Financing -241.95
Net change in Cash 20.23
Free Cash Flow 888.86
Particulars MAR 2022 (Values in Cr)
Net Income 667.58
Cash from Operations 514.25
Cash from Investing -136.13
Cash from Financing -156.48
Net change in Cash 37.38
Free Cash Flow 589.44
Particulars MAR 2021 (Values in Cr)
Net Income 467.67
Cash from Operations 491.98
Cash from Investing -311.39
Cash from Financing -75.66
Net change in Cash -4.51
Free Cash Flow 602.82
Particulars MAR 2020 (Values in Cr)
Net Income 404.51
Cash from Operations 493.32
Cash from Investing -413.44
Cash from Financing 7.32
Net change in Cash 0.79
Free Cash Flow 596.39
Particulars MAR 2024 (Values in Cr)
Net Income 408.77
Cash from Operations 479.16
Cash from Investing -381.57
Cash from Financing -13.77
Net change in Cash -24.70
Free Cash Flow 529.48
Particulars MAR 2023 (Values in Cr)
Net Income 579.39
Cash from Operations 638.60
Cash from Investing -236.86
Cash from Financing -243.14
Net change in Cash 12.81
Free Cash Flow 783.21
Particulars MAR 2022 (Values in Cr)
Net Income 722.44
Cash from Operations 421.63
Cash from Investing -90.29
Cash from Financing -156.48
Net change in Cash 23.11
Free Cash Flow 496.82
Particulars MAR 2021 (Values in Cr)
Net Income 413.97
Cash from Operations 439.16
Cash from Investing -257.65
Cash from Financing -76.55
Net change in Cash -4.48
Free Cash Flow 550.00
Particulars MAR 2020 (Values in Cr)
Net Income 357.59
Cash from Operations 445.15
Cash from Investing -366.64
Cash from Financing 8.57
Net change in Cash 0.67
Free Cash Flow 548.22
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 36.86 3.50 491.45 37.54 / 77.70
BLISS GVS PHARMA LTD 175.85 22.01 1.83 1852.87 92.25 / 179.65
CIPLA LTD 1447.35 25.32 4.12 116889.80 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 403.70 140.17 4.09 1188.13 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 55.77 10.90 491.45 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.90 45.61 7.28 2168.01 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6603.60 128.25 24.30 16509.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 175.85 22.93 1.80 1852.87 92.25 / 179.65

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1284.60
  • 26 Days 1293.60
  • 10 Days 1291.30
  • 50 Days 1268.50
  • 12 Days 1285.90
  • 100 Days 1175.30
  • 20 Days 1285.80
  • 200 Days 715.10
1283.13
PIVOT
First Resistance 1303.22
Second Resistance 1330.08
Third Resistance 1350.17
First Support 1256.27
Second Support 1236.18
Third Support 1209.32
RSI 46.64
MACD -7.67
Commodity Channel Index (CCI) -123.32
ADX 10.05
Williams % R -78.26

Over 1 Month

down

0.60

Over 3 Months

down

5.13

Over 6 Months

down

90.13

Over 1 Year

down

84.56

Over 3 Years

down

34.87

Over 5 Years

down

49.77

SUVEN PHARMACEUTICALS LTD Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

SUVEN PHARMACEUTICALS LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
22.26
Promoter Holdings
50.1
FII
10.69
DII
16.93
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Berhyanda Limited Shareholding of Promoter and Promoter Group 1.27539592E8 50.1
Jasti Property And Equity Holdings Private Limited Public Shareholding 2.5192957E7 9.9
Dsp Healthcare Fund Public Shareholding 1.3744829E7 5.4
Sbi Life Insurance Co. Ltd Public Shareholding 4849834.0 1.91
Uti Small Cap Fund Public Shareholding 4798617.0 1.89
Goldman Sachs Funds - Goldman Sachs India Equity P Public Shareholding 3018882.0 1.19
Hsbc Small Cap Fund Public Shareholding 2871511.0 1.13
Invesco India Manufacturing Fund Public Shareholding 2623332.0 1.03
Tata Nifty 500 Multicap India Manufacturing 50:30: Public Shareholding 2609218.0 1.02

SUVEN PHARMACEUTICALS LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2022-09-09 1.0 Interim 2022-09-12 Equity shares 2022-09-09 5.0 Special 2022-09-12 Equity shares 2022-05-13 1.0 Interim 2 2022-05-17 Equity shares 2022-05-13 1.0 Special 2022-05-17 Equity shares 2022-02-15 1.0 Interim 2022-02-16 Equity shares 2022-02-15 2.0 Special 2022-02-16 Equity shares 2021-08-13 1.0 Final 2021-08-17 Equity shares 2021-02-17 1.0 Interim 2021-02-18 Equity shares
Ex-Date Ex-Bonus Ratio
2020-09-28 2020-09-25 1:1
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About SUVEN PHARMACEUTICALS LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by SUVEN PHARMACEUTICALS LTD

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Suven Pharmaceuticals Ltd?

Answer Field

The share price of Suven Pharmaceuticals Ltd for NSE is ₹ 1265 and for BSE is ₹ 1265.9.

What is the Market Cap of Suven Pharmaceuticals Ltd?

Answer Field

The market cap of Suven Pharmaceuticals Ltd for NSE is ₹ 3,22,02.47 Cr. and for BSE is ₹ 3,22,25.38 Cr. as of now.

What is the 52 Week High and Low of Suven Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Suven Pharmaceuticals Ltd for NSE is ₹ 1360.00 and ₹ 585.20 and for BSE is ₹ 1359.00 and ₹ 586.10.

How to Buy Suven Pharmaceuticals Ltd share?

Answer Field

You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Suven Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 84.56%.

What is the Current Share Price of Suven Pharmaceuticals Ltd?

Answer Field

Suven Pharmaceuticals Ltd share price is for NSE ₹ 1265 & for BSE ₹ 1265.9 as on Dec 13 2024 03:29 PM.

What is the Market Cap of Suven Pharmaceuticals Ltd Share?

Answer Field

The market cap of Suven Pharmaceuticals Ltd for NSE ₹ 3,22,02.47 & for BSE ₹ 3,22,25.38 as on Dec 13 2024 03:29 PM.

What is the P/E Ratio of Suven Pharmaceuticals Ltd Share?

Answer Field

As on Dec 13 2024 03:29 PM the price-to-earnings (PE) ratio for Suven Pharmaceuticals Ltd share is 131.06.

What is the PB ratio of Suven Pharmaceuticals Ltd Share?

Answer Field

As on Dec 13 2024 03:29 PM, the price-to-book (PB) ratio for Suven Pharmaceuticals Ltd share is 86.66.

How to Buy Suven Pharmaceuticals Ltd Share?

Answer Field

You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Suven Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Suven Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Suven Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader